REGN241206C630000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Earned a 16% CAGR Over the Last Five Years
Maia Biotechnology, Regeneron Expand Clinical Supply Deal
Express News | Maia Biotechnology Inc - Expects New Patient Enrollment to Begin Soon
Express News | Maia Biotechnology Inc - Expansion of 2021 Clinical Supply Agreement for Phase 2 Trial
Medigene Receives Milestone Payment From Regeneron Pharmaceuticals, Inc.
RBC Capital Remains a Buy on Regeneron (REGN)
Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy
Sanofi (SNY.US) / Regeneron (REGN.US) Dupilumab injection approved for clinical treatment of pure lichen in China.
The dupilumab injection submitted by Sanofi (SNY.US) has been approved for a new clinical trial implicit license.
Regeneron Pharmaceuticals Unusual Options Activity
Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock?
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?
Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $895
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,110
Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Earned a 15% CAGR Over the Last Five Years
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Catalyst Watch: Robotaxi IPO, OPEC+, Holiday Shopping Data, and Movie Blockbusters
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
High Alpha Stocks That Are Rated 'Overweight' – MS
Regeneron Pharmaceuticals's Options: A Look at What the Big Money Is Thinking